Virometix, a Schlieren, Switzerland-based developer of vaccines, raised CHF 5.0m in equity financing.
The round was backed by existing shareholders and new private investors with experience in the life science sector.
The company intends to use the funds for further development of its vaccines and expansion of its operations.
Led by Arin Ghasparian, CEO, Virometix is advancing vaccine candidates for infectious and viral diseases and cancer. It is starting a phase 1 clinical study for its lead vaccine V306 for RSV*, which has shown excellent safety and strong efficiency in preclinical models.
*Respiratory Syncytial Virus (RSV) is a seasonal respiratory virus that infects the lungs and breathing passages. It can spread via droplets sneezed or coughed into the air by an infected person. Otherwise healthy individuals infected with the virus typically recover within one to two weeks. However, RSV can cause severe lower respiratory tract illness (LRI) and other illnesses in newborns, small children, older adults and immunocompromised persons. RSV is very common: most children experience at least one infection in the first two years of life and about 5% of the older population become infected every year. A drug called Palivizumab is used for the prevention of severe illness in certain children who are at high risk. It is not effective in curing children already suffering from disease. Currently there is no vaccine available.